

Department of Molecular Mechanisms of Disease
of the Vetsuisse Faculty University of Zurich

Chair of Department: Prof. Dr. med. vet. et phil. II Michael O. Hottiger

Musculoskeletal Research Unit (MSRU), DMMD

Work under the academic supervision of
Prof. Dr. rer. nat. Ulrich Siler, Dr. med. vet. Katja Nuss

**A study on the efficacy of a lentiviral vector for treatment of
immunodeficiency in a mouse disease model**

Inaugural Thesis

to obtain the title of Doctor from the
Vetsuisse Faculty University of Zürich

submitted by

Felix Lehner

Veterinarian
of Linz, Austria

Approved at the request of

Prof. Dr. med. vet. et phil. II Michael O. Hottiger, Supervisor
Prof. Dr. rer. nat. Ulrich Siler, Co-Supervisor

2023

Table of contents

Summary	7
Zusammenfassung	8
1 Introduction.....	9
1.1 Definition of the challenge	9
1.2 Goal and hypothesis of the study.....	9
2 Literature review.....	10
2.1 Chronic granulomatous disease	10
2.1.1 Epidemiology.....	10
2.1.2 Causes of CGD	11
2.1.3 Symptoms and Diagnosis of CGD.....	12
2.1.4 Current therapy options of CGD.....	13
2.1.5 Hematopoietic stem cell transplantation (HSCT).....	14
2.2 Gene therapy in CGD	15
2.2.1 The state of gene therapy	15
2.2.2 The state of gene therapy in CGD	19
2.2.3 Vectors for gene therapy in CGD.....	21
2.2.4 <i>In vivo</i> testing of gene therapy in CGD	22
2.2.4.1 The mouse CGD disease model	22
2.2.4.2 Myeloablation via irradiation or chemotherapy	22
3 Materials and Methods.....	24
3.1 License for animal experiments.....	24
3.2 Pilot studies.....	24
3.3 Animals.....	24
3.3.1 Experimental animals	26
3.3.2 Animal housing and handling	28
3.3.3 Monitoring of health status	28
3.3.4 Intensive care	29
3.4 Test Item and Reference Item.....	29
3.5 Administration of Test and Reference Item.....	30

3.5.1	Irradiation	30
3.5.2	Administration of the Test and Reference Items	31
3.6	Blood collection	31
3.6.1	Blood collection from the tail vein	31
3.6.2	Blood collection from the heart at sacrifice	32
3.7	Sacrifice	32
3.7.1	Termination criteria	32
3.7.2	Tissue harvest after sacrifice	33
3.8	Analyses	34
3.8.1	Analysis of lineage distribution and p47phox transgenic protein expression in blood cells	34
3.8.2	Analysis of the function of p47phox transgenic protein in myeloid blood cells	36
3.8.3	Analysis of UZH1p47CGD vector copy number in blood cells	38
3.9	Statistical analysis	41
<hr/>		
4	Results	43
4.1	Injections	43
4.2	Animals	43
4.3	Body weight progression	44
4.4	Lineage distribution and p47phox expression in blood cells *	44
4.4.1	Percentage of p47phox expression in blood cells	44
4.4.2	Mean fluorescence intensity (MFI) of p47phox in p47phox expressing cells	49
4.4.3	Lineage distribution	49
4.5	DHR analysis in myeloid blood cells *	50
4.5.1	Percentage of Rho positive granulocytes	51
4.5.2	MFI of Rho positive granulocytes	52
4.6	Analysis of UZH1p47CGD vector copy number in blood cells *	53
4.6.1	Mean UZH1p47CGD vector copy number in blood cells	53
4.6.2	Engraftment of donor cells measured in the blood	54
4.7	Special events	55
<hr/>		
5	Discussion	58

5.1	Animal care	58
5.2	Weight progression	58
5.3	Lineage distribution and p47phox expression in blood cells.....	59
5.3.1	Percentage of p47phox expression in blood cells	59
5.3.2	Mean fluorescence intensity (MFI) of p47phox in p47phox expressing cells	61
5.3.3	Lineage distribution	61
5.4	DHR analysis in myeloid blood cells	62
5.4.1	Percentage of rhodamine positive blood granulocytes	62
5.4.2	MFI of rhodamine positive granulocytes.....	63
5.5	Vector copy numbers in the blood.....	64
5.6	Conclusive statement	65

6	Reference list	67
7	List of abbreviations	77
8	Annexes	78
8.1	Pilot studies.....	78
8.1.1	Pilot study 1	78
8.1.2	Pilot study 2	79
8.1.3	Pilot study 3	80
8.2	Tables.....	82
8.2.1	Analyses.....	82
8.2.2	Animal body weights	85
8.2.3	Injections of Test and Reference Items.....	91
8.2.4	P47phox expression, MFI of p47phox+ cells and lineage distribution in blood over time	93
8.2.4.1	P47phox expression in granulocytes, monocytes, B cells and T cells in blood	117
8.2.4.2	P47phox MFI in granulocytes, monocytes, B cells and T cells in blood	125
8.2.4.3	Lineage distribution.....	135
8.2.5	DHR.....	140

8.2.6	VCN and Engraftment.....	162
8.2.6.1	VCN.....	169
8.2.6.2	Engraftment.....	171
8.3	Figures.....	174
8.3.1	Figures regarding animal caretaking.....	175
8.3.2	P47phox expression.....	179
8.3.3	MFI.....	183
8.3.4	Lineage distribution.....	187
8.3.5	DHR.....	191
8.3.6	VCN.....	194
8.3.7	Engraftment.....	195

Acknowledgements

Curriculum Vitae
